Long-term efficacy and safety of exemestane in the treatment of breast cancer

Exemestane, a steroidal aromatase inhibitor, is licensed for postmenopausal patients with estrogen receptor (ER)-positive breast cancer as second-line therapy in metastatic disease following antiestrogen failure and as part of sequential adjuvant therapy following initial tamoxifen. This study is a...

Full description

Saved in:
Bibliographic Details
Main Authors: Walker, GA, Xenophontos, M, Chen, LC, Cheung, KL
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2013
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616141/
https://ncbi.nlm.nih.gov/pubmed/23569364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S42223
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items